´ëÇѾÏÇÐȸ Á¦2ȸ AACR(American Association for Cancer Research)-KCA(Korean Cancer Association) Joint Conference on Precision Medicine in Solid Tumors ¹× Á¦24Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö 2 : 2021-11-12±³À°ÀÏÀÚ : 2021-11-12
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£ È»ó °ÀÇ) ¹× ¼¿ï·Ôµ¥È£ÅÚ 2Ãþ Å©¸®½ºÅ»º¼·ë 2°³·ë
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) Á¦2ȸ AACR(American Association for Cancer Research)-KCA(Korean Cancer Association) Joint Conference on Precision Medicine in Solid Tumors ¹× Á¦24Â÷ ´ëÇѾÏÇÐȸ Ãß°è½ÉÆ÷Áö¾ö 2 ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ :
cancer2@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 300,000¿ø
ºñ°í 1. »çÀüµî·Ï: 1) ȸ¿ø 10¸¸¿ø, 2) ºñȸ¿ø 15¸¸¿ø, 3) ¾÷ü¹×¿¬±¸¼Ò 20¸¸¿ø, 4) Trainee ¹«·á2. ÀϹݵî·Ï: 1) ȸ¿ø 20¸¸¿ø, 2) ºñȸ¿ø 25¸¸¿ø, 3) ¾÷ü¹×¿¬±¸¼Ò 30¸¸¿ø, 4) Trainee 3¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-12 Room A 08:00~08:30 Tumor microenvironment: Challenges and opportunities °í±Ô¿µ(KAIST)
ÈÞ½Ä 11-12 08:30~08:50 ÈÞ½Ä ()
±³À°½Ã°£ 11-12 Room A 08:50~09:15 Using a cancer dependency map William C. Hahn(Dana-Farber Cancer Institute, Boston, MA, USA)
±³À°½Ã°£ 11-12 Room A 09:15~09:40 Creation of tumor assembloids recapitulating epithelial-stromal interaction in human cancers: Role of Foxa1(Forkhead Box A1)-Hedgehog-Bmp axis in tumor plasticity ½Å±ÙÀ¯(POSTECH)
±³À°½Ã°£ 11-12 Room A 09:40~10:05 Organoid modeling of lung disease and lung cancer Carla F. Kim(Boston Children¡¯s Hospital, Boston, MA, USA)
±³À°½Ã°£ 11-12 Room A 10:05~10:30 The cooperation of YAP(yes-associated protein) and AP-1(activator protein 1) in ductal cell-derived pancreatic cancer development ÀÓ´ë½Ä(KAIST)
±³À°½Ã°£ 11-12 Room B 08:50~09:15 Updates and advances in personalized cancer vaccines Catherine J. Wu(Dana-Farber Cancer Institute, Boston, MA, USA)
±³À°½Ã°£ 11-12 Room B 09:15~09:40 TCR(t-cell receptor)-seq analysis in anti-PD-1(programmed death-1) treated patients ½ÅÀÇö(KAIST)
±³À°½Ã°£ 11-12 Room B 09:40~10:05 Defining the actionable genome David B. Solit(Memorial Sloan Kettering Cancer Center, New York, NY, USA)
±³À°½Ã°£ 11-12 Room B 10:05~10:30 Updates in gastric cancer immunogenomics ÀÌÁö¿¬(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 11-12 10:30~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 11-12 Room A 10:50~11:15 Acquired resistance to KRAS(kirsten rat sarcoma viral oncogene homolog) G12C inhibition Andrew J. Aguirre(Dana-Farber Cancer Institute, Boston, MA, USA)
±³À°½Ã°£ 11-12 Room A 11:15~11:40 Resistance mechanism and overcome strategy to Raf(receptor accessory factor) inhibitor Belvarafenib ±èÅ¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 11:40~12:05 To be announced Kevan Shokat(University of California San Francisco, San Francisco, CA, USA)
±³À°½Ã°£ 11-12 Room A 12:05~12:30 Novel route to control KRAS(kirsten rat sarcoma viral oncogene homolog)-driven cancers ±è¼ºÈÆ(¿¬¼¼´ë ¾à´ë)
±³À°½Ã°£ 11-12 Room B 10:50~11:15 The discovery of context specific paralog dependence in cancer through combinatorial CRISPR(clustered regularly interspaced short palindromic repeats) screens William R. Sellers(Broad Institute of MIT and Harvard, Cambridge, MA, USA)
±³À°½Ã°£ 11-12 Room B 11:15~11:40 To be announced Á¤ÀçÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 11:40~12:05 Accelerating inhibitor discovery to functionally annotate deubiquitinating enzymes Sarah J. Buhrlage(Dana-Farber Cancer Institute, Boston, MA, USA)
±³À°½Ã°£ 11-12 Room B 12:05~12:30 Microfabricated assays to investigate tumor microenvironment Á¤¼®(°í·Á´ë)
½Ä»ç 11-12 12:30~13:10 ½Ä»ç ()
±³À°½Ã°£ 11-12 Room A 13:10~13:30 Optimizing clinical outcomes for Asian patients with EGFR(epidermal growth factor receptor) mutation-positive NSCLC(non-small-cell lung carcinoma) ÀÌÀ±±Ô(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 11-12 Room B 13:10~13:30 Optimizing treatment for HR+(hormone receptor-positive), HER2-(human epidermal growth factor receptor 2-negative) metastatic breast cancer patients ¼ÕÁÖÇõ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 13:30~13:50 Lung cancer Á¤Çö¾Ö(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11-12 Room B 13:30~13:50 Tumor agnostic therapies toward precision medicine era Á¶º´Ã¶(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 13:50~14:10 Treatment for advanced EGFR(epidermal growth factor receptor) T790M(threonine at amino acid position 790) positive NSCLC(non-small-cell lung carcinoma) ±èŹÎ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 13:50~14:10 Pancreatic cancer õÀç°æ(Â÷ÀÇ´ë)
ÈÞ½Ä 11-12 14:10~14:30 ÈÞ½Ä ()
±³À°½Ã°£ 11-12 Room A 14:30~14:50 NCCN(National Comprehensive Cancer Network) clinical practice guideline of adolescent and young adult oncology ÀÓ¿¬Á¤(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 14:50~15:10 Extracranial germ cell tumors in adolescents and young adults Çѽ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 15:10~15:30 Adenocarcinoma in adolescents and young adults ¾çÈñ¹ü(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-12 Room B 14:30~14:50 Recent advance in the development of novel, ive and potent FGFR(fibroblast growth factor receptors) inhibitors ±èÈñÁØ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 14:50~15:10 HER2-(human epidermal growth factor receptor 2-negative) targeted therapies - A role beyond breast and gastric cancer ±è¹Ì¼Ò(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 15:10~15:30 Inhibitors of MET(mesenchymal–epithelial transition) and RET(rearrangement during transfection) in non-small cell lung cancer (NSCLC) È«¹ÎÈñ(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 11-12 15:30~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 11-12 Room A 15:50~16:15 Experience of molecular tumor board in sponsor-initiated trial ±èÁ¤Àº(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 16:15~16:40 Investigator-initiated personalized treatment by molecular tumor board ±èÁöÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-12 Room A 16:40~17:05 Nationwide precision medicine to accelerate targeted cancer therapies À̼öÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 15:50~16:15 RTOG 1119: Phase II randomized study of whole brain radiotherapy/stereotactic radiosurgery with concurrent lapatinib in patients with brain metastases from HER2-positive breast cancer - a collaborative study of NRG Oncology and KROG ±èÀξÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 16:15~16:40 Result and lesson KROG(Korean Radiation Oncology Group) 08-06 trial ±è¿ë¹è(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-12 Room B 16:40~17:05 PBT(Proton Beam Radiotherapy) vs RFA(Radiofrequency Ablation) treatment for recurrent hepatocellular carcinoma: A randomized controlled phase 3 non-inferiority APROH trial ±èÅÂÇö(±¹¸³¾Ï¼¾ÅÍ)